Accordingly, it has been previously demonstrated that the combined therapy of SRLs with PEGV can normalize IGF-I levels in virtually all patients and control tumor size in a vast majority of patients if an adequate dose of PEGV is used (32). Here, IGF1 is linked to neoplasm.